Edition:
International

Medical Equipment, Supplies & Distribution

Page 1

10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc

Tuesday, 27 Jul 2021 07:44am EDT

July 27 (Reuters) - Bio Rad Laboratories Inc ::10X GENOMICS INC - ENTERED INTO A GLOBAL SETTLEMENT AND CROSS-LICENSE AGREEMENT WITH BIO-RAD LABORATORIES, INC..10X GENOMICS INC - AGREEMENT RESOLVES ALL OUTSTANDING LITIGATION AND OTHER PROCEEDINGS BETWEEN TWO COS ACROSS ALL JURISDICTIONS AROUND THE WORLD.10X GENOMICS - AGREEMENT GRANTS EACH CO NON-EXCLUSIVE, WORLDWIDE, ROYALTY-BEARING LICENSE TO DEVELOP PRODUCTS,SERVICES RELATED TO SINGLE CELL ANALYSIS.10X GENOMICS INC - CROSS LICENSE EXCLUDES PRODUCTS RELATED TO SPATIAL ANALYSIS AND IN SITU ANALYSIS, ALSO EXCLUDES DIGITAL PCR PRODUCTS IN CASE OF 10X.10X GENOMICS INC - PURSUANT TO AGREEMENT, CO SHALL PAY BIO-RAD $29.4 MILLION IN ROYALTIES AND INTEREST.10X GENOMICS INC - CO SHALL PAY BIO-RAD IN ROYALTIES AND INTEREST RELATED TO SALES OF SUCH GEM PRODUCTS BETWEEN NOVEMBER 14, 2018 AND MARCH 31, 2021.10X GENOMICS - IN CONNECTION WITH AGREEMENT CO EXPECTS $15.4 MILLION IN ACCRUED ROYALTIES, INTEREST WILL BE REVERSED TO CO'S FINANCIAL STATEMENTS IN Q2.

10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc

Tuesday, 27 Jul 2021 07:44am EDT

July 27 (Reuters) - Bio Rad Laboratories Inc ::10X GENOMICS INC - ENTERED INTO A GLOBAL SETTLEMENT AND CROSS-LICENSE AGREEMENT WITH BIO-RAD LABORATORIES, INC..10X GENOMICS INC - AGREEMENT RESOLVES ALL OUTSTANDING LITIGATION AND OTHER PROCEEDINGS BETWEEN TWO COS ACROSS ALL JURISDICTIONS AROUND THE WORLD.10X GENOMICS - AGREEMENT GRANTS EACH CO NON-EXCLUSIVE, WORLDWIDE, ROYALTY-BEARING LICENSE TO DEVELOP PRODUCTS,SERVICES RELATED TO SINGLE CELL ANALYSIS.10X GENOMICS INC - CROSS LICENSE EXCLUDES PRODUCTS RELATED TO SPATIAL ANALYSIS AND IN SITU ANALYSIS, ALSO EXCLUDES DIGITAL PCR PRODUCTS IN CASE OF 10X.10X GENOMICS INC - PURSUANT TO AGREEMENT, CO SHALL PAY BIO-RAD $29.4 MILLION IN ROYALTIES AND INTEREST.10X GENOMICS INC - CO SHALL PAY BIO-RAD IN ROYALTIES AND INTEREST RELATED TO SALES OF SUCH GEM PRODUCTS BETWEEN NOVEMBER 14, 2018 AND MARCH 31, 2021.10X GENOMICS - IN CONNECTION WITH AGREEMENT CO EXPECTS $15.4 MILLION IN ACCRUED ROYALTIES, INTEREST WILL BE REVERSED TO CO'S FINANCIAL STATEMENTS IN Q2.

Kossan Rubber Industries Posts QTRLY Profit Attributable Of 1.06 Billion RGT

Tuesday, 27 Jul 2021 06:12am EDT

July 27 (Reuters) - Kossan Rubber Industries Bhd ::QTRLY PROFIT ATTRIBUTABLE 1.06 BILLION RGT VERSUS 131.1 MILLION RGT.QTRLY REVENUE 2.24 BILLION RGT VERSUS 701.7 MILLION RGT.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary